Pyrrolidinedithiocarbamate ammonium 是一种选择性的、能透过血脑屏障的NF-Κb抑制剂。

Pyrrolidinedithiocarbamate ammonium, a selective NF-κB inhibitor, inhibits translation of nitric oxide synthase mRNA to prevent induction.

Pretreatment of cells with PDTC (3-1000 mM) dose-dependently attenuate IL-8 production. Furthermore, PDTC (100 mM) suppresses the accumulation of IL-8 mRNA. PDTC inhibites the activation of NF-kB, because PDTC suppresses both NF-kB DNA binding and NF-kB-dependent transcriptional activity. Taken together, our data demonstrate that NF-kB inhibition with PDTC decrease IL-8 production by intestinal epithelial cells[1].

The DSS+PDTC-treated groupⅡ exhibited suppression of shortening of intestinal length and reduction of DAI score. Activated NF-κB level and IL-1β and TNF-α levels are significantly lower in DSS+PDTC-treated groupⅡ. These findings suggest that suppression of NF-κB activity by PDTC can delay the healing of mucosal tissue defects (erosions or ulcers) arising from inflammation, but that it can strongly suppress the expression of inf-lammatory cytokines (IL-1β and TNF-α), resulting in significant alleviation of colitis. PDTC is useful for the treatment of ulcerative colitis[2].

All binding studies are performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-l-Ig/PD-Ll-His binding assay, inhibitors are pre-incubated with PD-Ll-His (10 nM final) for 15 m in 4 μL of assay buffer, followed by addition of PD-l-Ig (20 nM final) in 1 μL of assay buffer and further incubation for 15 m. PD-L1 from either human, cyno, or mouse are used. HTRF detection is achieved using europium crypate-labeled anti- Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies are diluted in HTRF detection buffer and 5 μL is dispensed on top of binding reaction. The reaction mixture is allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) is obtained using an En Vision fluorometer. Additional binding assays are established between PD-1-Ig/PD-L2-His (20, 5 nM, respectively), CD80-His/PD-Ll-Ig (100, 10 nM, respectively) and CD80-His/CTLA4-Ig (10, 5 nM, respectively).

The human colon cancer cell line HT-29 is obtained and cells are grown in modified McCoy's 5A medium supplemented with 10% fetal bovine serum. To study the effect of PDTC on IL-8 production, HT-29 cells in 96-well plates are induced with 20 ng/mL of IL-1b for 18 h. Various concentrations (3-1000 mM) of PDTC or its vehicle (culture medium) are added to the cells 30 min prior to IL-1b stimulation. The concentration of IL-8 in the supernatant is determined using solid-phase enzyme-linked immunosorbent assay, as described previously employing the multiple antibody sandwich principle that specifically detects human IL-8[1].

5108-96-3

C5H12N2S2

164.29

1-Pyrrolidinedithiocarboxylic acid ammonium salt;Ammonium pyrrolidinedithiocarbamate;吡咯烷二硫代氨基甲酸铵;APDC;Pyrrolidinedithiocarbamate;吡咯烷二硫代甲酸铵;PDTC;Pyrrolidinedithiocarbamate ammonium

DMSO:16.4 mg/mL(100 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years